Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ZYBT
Zhengye Biotechnology Holding Limited
CAPPED RATING
Zhengye Biotechnology Holding Limited (ZYBT) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C+
Value
B-
Factor Score
3.0
/ 5.0
Growth
D-
Factor Score
0.9
/ 5.0
Profitability
C+
Factor Score
2.7
/ 5.0
Momentum
B
Factor Score
3.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
-3.4
Rev Growth YoY
-40.9%
Gross Margin
20.5%
Price Return 3M
-1.3%
Price Return 12M
-30.6%
Catalyst Signal
0.00
Market Cap
$71.1M
TTM Revenue
$116.4M
Price / Sales
0.6
ROE
-25.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | D- (0.9) | C+ (2.7) | B (3.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-08 | B- (3.0) | D- (0.8) | C+ (2.7) | C+ (2.7) | C+ (2.6) | C (2.4) |
| 2026-11-01 | B- (3.0) | D- (0.8) | C+ (2.7) | B- (3.1) | C+ (2.7) | C (2.5) |
| 2026-10-25 | B- (3.0) | D- (0.8) | C+ (2.7) | B- (3.0) | C+ (2.6) | C (2.4) |
| 2026-10-18 | B- (3.0) | D- (0.8) | C+ (2.7) | D+ (1.7) | C+ (2.6) | C (2.2) |
Page
1
of
4